Romidepsin for cutaneous T-cell lymphoma

Clinical Cancer Research

Volumn 18, Issue 13, 2012, Pages 3509-3515

  Prince, H Miles ^a,b   Dickinson, Michael ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BEXAROTENE; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DENILEUKIN DIFTITOX; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; INTERFERON; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 1; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTER 1B3; PANOBINOSTAT; PRALATREXATE; ROMIDEPSIN; STAT3 PROTEIN; UNCLASSIFIED DRUG; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIANGIOGENIC ACTIVITY; AREA UNDER THE CURVE; ASTHENIA; CANCER RELAPSE; CANCER STAGING; CHRONIC LEUKEMIA; CLINICAL FEATURE; CONTINUOUS INFUSION; CUTANEOUS T CELL LYMPHOMA; DRUG APPROVAL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TARGETING; DRUG TOLERABILITY; ENZYME INHIBITION; FATIGUE; FEBRILE NEUTROPENIA; FOOD AND DRUG ADMINISTRATION; GENE; GENE EXPRESSION; HEART ARRHYTHMIA; HISTONE ACETYLATION; HUMAN; MAXIMUM PLASMA CONCENTRATION; MDR1 GENE; MULTIPLE CYCLE TREATMENT; MYCOSIS FUNGOIDES; MYELOMA; NAUSEA; NEUTROPENIA; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN PHOSPHORYLATION; QT PROLONGATION; REVIEW; SEPSIS; SEZARY SYNDROME; SIDE EFFECT; ST SEGMENT DEPRESSION; T CELL LYMPHOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED STATES;

ANTIBIOTICS, ANTINEOPLASTIC; CLINICAL TRIALS AS TOPIC; DEPSIPEPTIDES; HISTONE DEACETYLASE INHIBITORS; HUMANS; LYMPHOMA, T-CELL, CUTANEOUS;

EID: 84863325822     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-3144     Document Type: Review

References (28)

1. Dickinson M, Johnstone RW, Prince HM. Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect. Invest New Drugs 2010;28[Suppl 1]:S3-20.
2. Bradner JE, West N, Grachan ML, Greenberg EF, Haggarty SJ, Warnow T, et al. Chemical phylogenetics of histone deacetylases. Nat Chem Biol 2010;6:238-43.
3. Ueda H, Manda T, Matsumoto S, Mukumoto S, Nishigaki F, Kawamura I, et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice. J Antibiot (Tokyo) 1994;47:315-23. (Pubitemid 24106522)
4. Frønsdal K, Saatcioglu F. Histone deacetylase inhibitors differentially mediate apoptosis in prostate cancer cells. Prostate 2005;62: 299-306. (Pubitemid 40129069)
5. Ito T, Ouchida M, Morimoto Y, Yoshida A, Jitsumori Y, Ozaki T, et al. Significant growth suppression of synovial sarcomas by the histone deacetylase inhibitor FK228 in vitro and in vivo. Cancer Lett 2005;224: 311-9. (Pubitemid 40725851)
6. Piekarz RL, Robey RW, Zhan Z, Kayastha G, Sayah A, Abdeldaim AH, et al. T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood 2004;103:4636-43. (Pubitemid 38745996)
7. Fouladi M, Furman WL, Chin T, Freeman BB 3rd, Dudkin L, Stewart CF, et al. Children's Oncology Group. Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report. J Clin Oncol 2006;24:3678-85. (Pubitemid 46630544)
8. Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 2002;8:718-28. (Pubitemid 34742100)
9. Woo S, Gardner ER, Chen X, Ockers SB, Baum CE, Sissung TM, et al. Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Clin Cancer Res 2009;15:1496-503.
10. Niesvizky R, Ely S, Mark T, Aggarwal S, Gabrilove JL, Wright JJ, et al. Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer 2011;117:336-42.
11. Byrd JC, Marcucci G, Parthun MR, Xiao JJ, Klisovic RB, Moran M, et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 2005;105:959-67. (Pubitemid 40170861)
12. Piekarz RL, Frye R, Prince HM, Kirschbaum MH, Zain J, Allen SL, et al. Phase 2 trial of romidepsin in patientswith peripheral T-cell lymphoma. Blood 2011;117:5827-34.
13. Piekarz RL, Frye R, Turner M, Wright JJ, Allen SL, Kirschbaum MH, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009;27:5410-7.
14. Whittaker SJ, Demierre MF, Kim EJ, Rook AH, Lerner A, Duvic M, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 2010;28:4485-91.
15. Robey RW, Zhan Z, Piekarz RL, Kayastha GL, Fojo T, Bates SE. Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176). Clin Cancer Res 2006;12:1547-55.
16. Bates SE, Zhan Z, Steadman K, Obrzut T, Luchenko V, Frye R, et al. Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma. Br J Haematol 2010;148:256-67.
17. Lin R, Hu J, Paul S, Schindler J, Woo M, Spence S, et al. Characteristics of thrombocytopenia in patients treated with oral panobinostat (LBH589). In: 51st American Society for Hematology (ASH) Annual Meeting and Exposition; 2009 Dec 5-8; New Orleans (LA). Washington (DC): ASH; 2009. Abstract 2740.
18. Bishton MJ, Harrison SJ, Martin BP, McLaughlin N, James C, Josefsson EC, et al. Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia. Blood 2011;117:3658-68.
19. Piekarz RL, Frye AR, Wright JJ, Steinberg SM, Liewehr DJ, Rosing DR, et al. Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res 2006;12:3762-73. (Pubitemid 44000258)
20. Munster PN, Rubin EH, Van Belle S, Friedman E, Patterson JK, Van Dyck K, et al. A single supratherapeutic dose of vorinostat does not prolong the QTc interval in patients with advanced cancer. Clin Cancer Res 2009;15:7077-84.
21. Mitchell TJ, John S. Signal transducer and activator of transcription (STAT) signalling and T-cell lymphomas. Immunology 2005;114: 301-12. (Pubitemid 40314803)
22. Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007;109:31-9. (Pubitemid 46053039)
23. Fantin VR, Loboda A, Paweletz CP, Hendrickson RC, Pierce JW, Roth JA, et al. Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. Cancer Res 2008;68:3785-94.
24. Khan O, Fotheringham S, Wood V, Stimson L, Zhang C, Pezzella F, Duvic M, et al. HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy. Proc Natl Acad Sci U S A 2010;107: 6532-7.
25. Ellis L, Pan Y, Smyth GK, George DJ, McCormack C, Williams-Truax R, et al. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res 2008;14:4500-10.
26. Prince HM, Whittaker S, Hoppe RT. How I treat mycosis fungoides and Sézary syndrome. Blood 2009;114:4337-53.
27. Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007;25:3109-15. (Pubitemid 47218059)
28. Duvic M, Dummer R, Becker J, Poulalhon N, Romero P, Bernengo M, et al. Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial. Eur J Cancer. In press.